RT @sebastianreuma: Cohorte ANSWER:Tocilizumab, etanercept, infliximab, abatacept, adalimumab, golimumab y certolizumab en #ArtritisReumato…
RT @sebastianreuma: Cohorte ANSWER:Tocilizumab, etanercept, infliximab, abatacept, adalimumab, golimumab y certolizumab en #ArtritisReumato…
RT @sebastianreuma: Cohorte ANSWER:Tocilizumab, etanercept, infliximab, abatacept, adalimumab, golimumab y certolizumab en #ArtritisReumato…
Cohorte ANSWER:Tocilizumab, etanercept, infliximab, abatacept, adalimumab, golimumab y certolizumab en #ArtritisReumatoide. TCZ < rata suspensión por falta eficacia, ABT < rata suspensión por efecto adverso, ADA e IFX > rata suspensión por remisió
RT @RheumNow: Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ;…
RT @RheumNow: Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ;…
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study https://t.co/s44hTt5GNg
RT @RheumNow: Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ;…
RT @RheumNow: Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ;…
Biologic Survival study from Japan- ANSWER study w/ 4466 courses in 2494 pts (2009-17). Efficacy Survival best for ABA, TCZ; worst for IFX & CZP. Toxicity Dropouts most in IFX & ADA, least ABA & CZP. Remission best w/ ETN & ABA, least w/ GL